Controlling exit site infections: Does it decrease the incidence of catheter-related bacteremia in children on chronic hemodialysis?

Ali Mirza Onder, Jayanthi Chandar, Sheila Coakley, Denise Francoeur, Carolyn Abitbol, Gaston E Zilleruelo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The aim of this retrospective study was to investigate whether the application of a chlorhexidine-impregnated dressing (Biopatch®) at the exit site of tunneled-cuffed hemodialysis catheters has any effect on the incidence and etiology of catheter-related bacteremia (CRB). This study was carried out over a 5-year period in a single center, where, in the first 21/2; years, the exit sites were cleansed with betadine at every hemodialysis session and then covered with a transparent dressing (pre-Biopatch® Era). During the next 21/2; years, Biopatch® was applied to the exit site once a week after cleansing with betadine, and then covered with a transparent dressing (Biopatch® Era). The application of Biopatch® significantly decreased the incidence of exit site infections (ESI) (P < 0.05). However, there was no difference in the incidence of CRBs or their microbiological distribution. The improved ESI rate had no effect on the overall catheter survival time. The antimicrobial sensitivities of the Gram-positive microorganisms were statistically different for the 2 different types of infections (P < 0.05). In conclusion, even though Biopatch® is effective in decreasing the incidence of ESI, it has no effect on the incidence of CRB, the etiology of CRB, or the overall catheter survival time. The distinct difference between the antimicrobial sensitivities of the ESI and CRB suggests that they are not a spectrum of the same pathogenesis. These preliminary data support the intraluminal pathogenesis of CRB, rather than the exit site as a possible entry point for the extraluminal route.

Original languageEnglish
Pages (from-to)11-18
Number of pages8
JournalHemodialysis International
Volume13
Issue number1
DOIs
StatePublished - Feb 6 2009

Fingerprint

Bacteremia
Renal Dialysis
Catheters
Incidence
Infection
Bandages
Povidone-Iodine
Catheter-Related Infections
Chlorhexidine
Retrospective Studies

Keywords

  • Betadine
  • Biopatch®
  • Catheter survival
  • Catheter-related bacteremia
  • Chlorhexidine
  • Exit site infection
  • Sepsis

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Controlling exit site infections : Does it decrease the incidence of catheter-related bacteremia in children on chronic hemodialysis? / Onder, Ali Mirza; Chandar, Jayanthi; Coakley, Sheila; Francoeur, Denise; Abitbol, Carolyn; Zilleruelo, Gaston E.

In: Hemodialysis International, Vol. 13, No. 1, 06.02.2009, p. 11-18.

Research output: Contribution to journalArticle

@article{4908827365fc45dab9721d167b0d1684,
title = "Controlling exit site infections: Does it decrease the incidence of catheter-related bacteremia in children on chronic hemodialysis?",
abstract = "The aim of this retrospective study was to investigate whether the application of a chlorhexidine-impregnated dressing (Biopatch{\circledR}) at the exit site of tunneled-cuffed hemodialysis catheters has any effect on the incidence and etiology of catheter-related bacteremia (CRB). This study was carried out over a 5-year period in a single center, where, in the first 21/2; years, the exit sites were cleansed with betadine at every hemodialysis session and then covered with a transparent dressing (pre-Biopatch{\circledR} Era). During the next 21/2; years, Biopatch{\circledR} was applied to the exit site once a week after cleansing with betadine, and then covered with a transparent dressing (Biopatch{\circledR} Era). The application of Biopatch{\circledR} significantly decreased the incidence of exit site infections (ESI) (P < 0.05). However, there was no difference in the incidence of CRBs or their microbiological distribution. The improved ESI rate had no effect on the overall catheter survival time. The antimicrobial sensitivities of the Gram-positive microorganisms were statistically different for the 2 different types of infections (P < 0.05). In conclusion, even though Biopatch{\circledR} is effective in decreasing the incidence of ESI, it has no effect on the incidence of CRB, the etiology of CRB, or the overall catheter survival time. The distinct difference between the antimicrobial sensitivities of the ESI and CRB suggests that they are not a spectrum of the same pathogenesis. These preliminary data support the intraluminal pathogenesis of CRB, rather than the exit site as a possible entry point for the extraluminal route.",
keywords = "Betadine, Biopatch{\circledR}, Catheter survival, Catheter-related bacteremia, Chlorhexidine, Exit site infection, Sepsis",
author = "Onder, {Ali Mirza} and Jayanthi Chandar and Sheila Coakley and Denise Francoeur and Carolyn Abitbol and Zilleruelo, {Gaston E}",
year = "2009",
month = "2",
day = "6",
doi = "10.1111/j.1542-4758.2009.00348.x",
language = "English",
volume = "13",
pages = "11--18",
journal = "Hemodialysis International",
issn = "1492-7535",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Controlling exit site infections

T2 - Does it decrease the incidence of catheter-related bacteremia in children on chronic hemodialysis?

AU - Onder, Ali Mirza

AU - Chandar, Jayanthi

AU - Coakley, Sheila

AU - Francoeur, Denise

AU - Abitbol, Carolyn

AU - Zilleruelo, Gaston E

PY - 2009/2/6

Y1 - 2009/2/6

N2 - The aim of this retrospective study was to investigate whether the application of a chlorhexidine-impregnated dressing (Biopatch®) at the exit site of tunneled-cuffed hemodialysis catheters has any effect on the incidence and etiology of catheter-related bacteremia (CRB). This study was carried out over a 5-year period in a single center, where, in the first 21/2; years, the exit sites were cleansed with betadine at every hemodialysis session and then covered with a transparent dressing (pre-Biopatch® Era). During the next 21/2; years, Biopatch® was applied to the exit site once a week after cleansing with betadine, and then covered with a transparent dressing (Biopatch® Era). The application of Biopatch® significantly decreased the incidence of exit site infections (ESI) (P < 0.05). However, there was no difference in the incidence of CRBs or their microbiological distribution. The improved ESI rate had no effect on the overall catheter survival time. The antimicrobial sensitivities of the Gram-positive microorganisms were statistically different for the 2 different types of infections (P < 0.05). In conclusion, even though Biopatch® is effective in decreasing the incidence of ESI, it has no effect on the incidence of CRB, the etiology of CRB, or the overall catheter survival time. The distinct difference between the antimicrobial sensitivities of the ESI and CRB suggests that they are not a spectrum of the same pathogenesis. These preliminary data support the intraluminal pathogenesis of CRB, rather than the exit site as a possible entry point for the extraluminal route.

AB - The aim of this retrospective study was to investigate whether the application of a chlorhexidine-impregnated dressing (Biopatch®) at the exit site of tunneled-cuffed hemodialysis catheters has any effect on the incidence and etiology of catheter-related bacteremia (CRB). This study was carried out over a 5-year period in a single center, where, in the first 21/2; years, the exit sites were cleansed with betadine at every hemodialysis session and then covered with a transparent dressing (pre-Biopatch® Era). During the next 21/2; years, Biopatch® was applied to the exit site once a week after cleansing with betadine, and then covered with a transparent dressing (Biopatch® Era). The application of Biopatch® significantly decreased the incidence of exit site infections (ESI) (P < 0.05). However, there was no difference in the incidence of CRBs or their microbiological distribution. The improved ESI rate had no effect on the overall catheter survival time. The antimicrobial sensitivities of the Gram-positive microorganisms were statistically different for the 2 different types of infections (P < 0.05). In conclusion, even though Biopatch® is effective in decreasing the incidence of ESI, it has no effect on the incidence of CRB, the etiology of CRB, or the overall catheter survival time. The distinct difference between the antimicrobial sensitivities of the ESI and CRB suggests that they are not a spectrum of the same pathogenesis. These preliminary data support the intraluminal pathogenesis of CRB, rather than the exit site as a possible entry point for the extraluminal route.

KW - Betadine

KW - Biopatch®

KW - Catheter survival

KW - Catheter-related bacteremia

KW - Chlorhexidine

KW - Exit site infection

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=59249108813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249108813&partnerID=8YFLogxK

U2 - 10.1111/j.1542-4758.2009.00348.x

DO - 10.1111/j.1542-4758.2009.00348.x

M3 - Article

C2 - 19210272

AN - SCOPUS:59249108813

VL - 13

SP - 11

EP - 18

JO - Hemodialysis International

JF - Hemodialysis International

SN - 1492-7535

IS - 1

ER -